Active Ingredient(s):Ivosidenib FDA Approved: * July 20, 2018 Pharm Company: *AGIOS PHARMACEUTICALS INC Category:Cancer
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and for cholangiocarcinoma.
* May have multiple approval dates, manufacturers, or labelers.